Elanco Animal Health (ELAN) Shares Outstanding 2015–TTM

Name: Elanco Animal Health (ELAN) shares outstanding history 2015-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Elanco Animal Health annual shares outstanding for fiscal 2025 was 496 million shares, a decrease of 0.2% from 497 million shares in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

ELAN Annual Shares Outstanding

Shares Outstanding (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Shares Outstanding (M)	—	496M	497M	492M	488M	487M	441M	370M	314M	356M	356M	356M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ELAN Quarterly Shares Outstanding

Shares Outstanding (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Shares Outstanding (M)	—	506M	497M	497M	500M	499M	494M	498M	494M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Shares Outstanding at Comparable Companies

UTHR Shares Outstanding — United Therapeutics Corporation
NBIX Shares Outstanding — Neurocrine Biosciences Inc
RDY Shares Outstanding — Dr. Reddy’s Laboratories Ltd ADR
ALKS Shares Outstanding — Alkermes Plc
HIMS Shares Outstanding — Hims Hers Health Inc

More ELAN metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow

All ELAN financial statements → Interactive ELAN charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.